SANN — Santhera Pharmaceuticals Holding AG Share News
0.000.00%
Last trade - 00:00- CH₣220.90m
- CH₣220.41m
- CH₣77.19m
Brief: Santhera Announces Publication Of Long-Term Clinical Data With Vamorolone
Swiss stocks - Factors to watch on September 22
Brief: Santhera Pharmaceuticals Says Reveragen's Vision-DMD Study With Vamorolone In Duchenne Muscular Dystrophy Fully Enrolled
Brief: Santhera Pharmaceuticals Holding H1 Net Loss Widens To CHF 31.8 Million
Brief: Santhera Pharmaceuticals A Direct License Holder Of Vamorolone
Brief: Santhera Pharmaceuticals Holding Carries Out Capital Increase
Brief: Santhera Says UK's MHRA Renews EAMS Opinion For Idebenone
Swiss stocks - Factors to watch on June 17
Brief: Santhera Completes Capital Increase For Financing Arrangements
Brief: Santhera Receives Financing Commitment Of Up To CHF 20 Million
Brief: Santhera Completes Reveragen's Extension Study With Vamorolone In Duchenne Muscular Dystrophy
Brief: Santhera Says EMA'S CHMP Grants Clock-Stop Extension In Authorization Of Puldysa
Swiss stocks - Factors to watch on May 20
Brief: Santhera Pharmaceuticals Completes Enrollment Of Phase 3 Sideros Study With Puldysa
Brief: Santhera Signs Agreements In Gene Therapy Research For Congenital Muscular Dystrophy
Brief: Santhera And Cold Spring Harbor Laboratory To Investigate Lonodelestat In COVID-19-Related ARDS
Swiss stocks - Factors to watch on April 9
Brief: Santhera Completes Capital Increase To Create Shares For Iris
Brief: Santhera Enters Equity-Linked Financing With IRIS For Up To CHF 24 Million